Ali Tehrani
PhD
Co-Founder and Former CEO
👥Biography 个人简介
Ali Tehrani co-founded Zymeworks and developed the Azymetric bispecific antibody platform, which uses computational protein engineering to enable efficient heterodimerization of bispecific antibody heavy chains with high purity and manufacturability. His platform has been widely licensed by pharmaceutical companies for developing bifunctional antibody therapeutics across oncology. His work demonstrated that computational approaches to protein engineering can solve the manufacturability challenges that have historically limited bispecific antibody development.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Ali Tehrani 的研究动态
Follow Ali Tehrani's research updates
留下邮箱，当我们发布与 Ali Tehrani（Zymeworks）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment